Research shows that users lose 245% more weight using Noom Med with a GLP-1 (when appropriate) compared to Noom Weight
One conceived in the wake of recombinant DNA technology in the 70s, shaped by early anglerfish experiments in the 80s, and given further structure by elegant biochemical studies of GPCR signaling in the 90s
Qsymia vs Wegovy or Qsymia vs Zepbound outlines significant distinctions
People were matched on factors including age, sex, race, BMI, and diabetes status to create comparable groups of GLP-1 users and nonusers
WADA 2026 Prohibited List Status (Section S0) Retatrutide is not currently named explicitly on the World Anti-Doping Agency 2025 or 2026 Prohibited Lists but falls within section S0 (Non-Approved Substances), which covers any pharmacological substance not currently approved by a governmental health authority for human therapeutic use
Last reviewed: July 17, 2026 Last updated: July 17, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
